Answers are grounded in this paper and cite their sources.
Despite considerable efforts to develop effective therapies for glioblastoma (GBM), the prognosis for patients with GBM remains poor. Targeting DNA damage response proteins, such as ATR, alongside standard-of-care treatment options has emerged as a promising strategy. Here, we evaluate the ability of a next-generation macrocyclic ATR inhibitor, APR-333, to synergize with alkylating agents in preclinical GBM models. APR-333 potently inhibited ATR signaling and demonstrated robust synergy with lomustine in human GBM cell lines and in a murine flank tumor model. In an orthotopic GBM xenograft model, the combination of systemic lomustine with direct intracranial administration of APR-333 via convection-enhanced delivery (CED) substantially reduced tumor growth and increased animal survival. Free and nanoparticle-encapsulated APR-333 produced comparable efficacy, and this combination was well tolerated. These findings support further evaluation of APR-333 with lomustine and highlight the potential of this combination approach to address current treatment challenges and possibly improve outcomes for patients with GBM.
No takes yet. Share an insight, caveat, or question.
Josowitz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: